| Issue Date | Title | Author(s) |
| Jul-2023 | Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations | Wang, Jun; Zhang, Bicheng; Peng, Ling; Liu, Xiufeng; Sun, Jianguo; Su, Chunxia; Wang, Huijuan; Zhao, Zheng; Si, Lu; Duan, Jianchun; Zhang, Hongmei; Li, Mengxia; Zhu, Bo; Zhang, Li; Li, Jin; Guo, Jun; Luo, Rongcheng; Qiu, Wensheng; Ye, Dingwei; Chu, Qian; Cui, Jiuwei; Dong, Xiaorong; Fan, Yun; Gao, Quanli; Guo, Ye; He, Zhiyong; Li, Wenfeng; Lin, Gen; Liu, Lian; Liu, Yutao; Qin, Haifeng; Ren, Shengxiang; Ren, Xiubao; Wang, Yongsheng; Xue, Junli; Yang, Yunpeng; Yang, Zhenzhou; Yue, Lu; Zhan, Xianbao; Zhang, Junping; Ma, Jun; Qin, Shukui; Wang, Baocheng |
| 2019 | Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 | Tang, Pingzhang; Guo, Ye; Hu, Chaosu; Xu, Zhengang; Zhang, Chenping; Zhou, Liang; Ding, Jianhui; Guo, Ye; He, Xiaohui; Hu, Chaosu; Ji, Qinghai; Li, Jiang; Li, Zhiming; Sun, Yan; Tao, Lei; Wang, Shengzi; Xia, Yunfei; Xu, Zhengang; Yang, Ankui; Yi, Junlin; Yu, Aimin; Zhang, Bin; Zhang, Chenping; Zhong, Laiping; Zhou, Jundong; Zhou, Liang; Zhu, Guopei |
| 2019 | Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 | Lin, Yansong; Huang, Huiqiang; Guo, Ye; Chen, Libo; Bao, Jiandong; Chen, Ge; Chen, Libo; Cui, Yali; Ding, Yong; Guan, Haixia; Guo, Ye; Gao, Zairong; Huang, Huiqiang; Huang, Rui; Huang, Tao; Hou, Xiaorong; He, Xiayun; Li, Mei; Li, Shaohua; Li, Xiaoyi; Li, Xuena; Li, Yujun; Liang, Zhiyong; Luo, Yukun; Lin, Yansong; Lyu, Jing; Ma, Qingjie; Niu, Lijuan; Sun, Wenhai; Wang, Feng; Wang, Renfei; Wei, Feng; Xia, Yu; Yang, Aiming; Zhang, Bin; Zhang, Bo; Zhang, Guang; Zhang, Hong; Zhang, Li; Zheng, Xiangqian; An, Rui; Fang, Jugao; Fan, Youben; Gao, Ming; Guo, Zhuming; Huang, Gang; Ji, Qinghai; Jiang, Ningyi; Jiang, Yuxin; Kuang, Anren; Li, Fang; Li, Sijin; Li, Yaming; Liu, Shaoyan; Sun, Hui; Shan, Zhongyan; Tan, Jian; Tian, Wen; Wang, Jing; Wang, Tie; Xing, Xiaoping; Xu, Zhengang; Zhang, Fuquan; Zhao, Jiajun; Zhao, Yupei; Zhu, Jingqiang; Li, Hui; Li, Jiao; Li, Li; Zhang, Yingjie; Zhao, Teng |
| Jan-2024 | Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific | Guo, Ye; Nakashima, Torahiko; Cho, Byoung Chul; Lim, Darren W. -T.; Yang, Muh-Hwa; Lou, Pei-Jen; Corry, June; Lin, Jin Ching; Zhu, Guo Pei; Kim, Kyung Hwan; Zhang, Bin; Li, Zhiming; Hong, Ruey-Long; Ng, Junice Yi Siu; Tan, Ee Min; Liu, Yan Ping; Stylianou, Con; Spiteri, Carmel; Porceddu, Sandro |
| Sep-2021 | Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia | Lee, Yong-Pyo; Yoon, Sang Eun; Song, Yuqin; Kim, Seok Jin; Yoon, Dok Hyun; Chen, Tsai-Yun; Koh, Young Il; Kang, Ka Won; Lee, Ho Sup; Wei, Kevin Tay Kuang; Lim, Soon Thye; Poon, Michelle; Irawan, Cosphiadi; Zhao, Weili; Do, Young Rok; Lee, Mark Hong; Ng, Soo Chin; Lee, Won-Sik; Guo, Ye; Zhang, Huilai; Kang, Hye-Jin; Yun, Hwan Jung; Kim, Hyo Jung; Lung, Daryl Tan Chen; Kwak, Jae-Yong; Han, Jae Joon; Mun, Yeung-Chul; Oh, Sung Yong; Shim, Hyeok; Kwon, Jung Hye; Sohn, Byeong Seok; Park, Seong Kyu; Jo, Jae Cheol; Ko, Young Hyeh; Jun, Zhu; Kim, Won Seog |
| Aug-2020 | The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial | Shi, Yuankai; Wu, Jianqiu; Wang, Zhen; Zhang, Liling; Wang, Zhao; Zhang, Mingzhi; Cen, Hong; Peng, Zhigang; Li, Yufu; Fan, Lei; Guo, Ye; Ma, Liping; Cui, Jie; Gao, Yuhuan; Yang, Haiyan; Zhang, Hongyu; Wang, Lin; Zhang, Weihua; Zhang, Huilai; Xie, Liping; Jiang, Ming; Zhou, Hui; Shuang, Yuerong; Su, Hang; Ke, Xiaoyan; Jin, Chuan; Du, Xin; Du, Xin; Liu, Li; Xi, Yaming; Ge, Zheng; Feng, Ru; Zhang, Yang; Zhou, Shengyu; Xie, Fan; Gao, Chao |
| 15-Nov-2022 | Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China | Song, Yuqin; Ying, Zhitao; Yang, Haiyan; Guo, Ye; Li, Wenyu; Zou, Dehui; Wu, Jianqiu; Tian, Alex; Huang, Tony; Zhou, Zisong; Ma, Meilin; Yang, Su; Qin, Yun; Zhu, Jun |
| Aug-2022 | Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study | Zheng, Xiangqian; Ji, Qinghai; Sun, Yuping; Ge, Minghua; Zhang, Bin; Cheng, Ying; Lei, Shangtong; Shi, Feng; Guo, Ye; Li, Linfa; Chen, Lu; Shao, Jingxin; Zhang, Wanli; Gao, Ming |
| Jul-2023 | Functional characterization and structural basis of a dual-function flavonoid 2'-O-glycosyltransferase from Scutellaria baicalensis | Li, Junhao; Wang, Zilong; Du, Xueqing; Guo, Ye; Wang, Haotian; Liu, Chenrui; Li, Fudong; Qiao, Xue; Agren, Hans; He, Chao; Guo, Dean |
| Jul-2023 | Functional characterization and structural basis of a dual-function flavonoid 2'-O-glycosyltransferase from Scutellaria baicalensis | Li, Junhao; Wang, Zilong; Du, Xueqing; Guo, Ye; Wang, Haotian; Liu, Chenrui; Li, Fudong; Qiao, Xue; Agren, Hans; He, Chao; Guo, Dean |
| 2-Nov-2023 | Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Lin, Ningjing; Sun, Xiuhua; Zhou, Hui; Zou, Liqun; Zhou, Keshu; Liu, Lihong; Yang, Haiyan; Hu, Kai; Cai, Qingqing; Liu, Yao; Jin, Jie; Zhang, Liling; Li, Wenyu; Guo, Ye; Yang, Wei; Luo, Feng; Li, Yanyan; Zhang, Mengqi; Lu, Feinan; Song, Yuqin; Zhu, Jun |
| 2023 | Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study | Zhang, Dongming; Liu, Xiaoyan; Shen, Fangfang; Zhao, Dahai; Shi, Yuequan; Zhang, Haoran; Liu, Jia; Gao, Xiaoxing; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Gao, Junzhen; He, Min; Liu, Yonggang; Yang, Xiaoling; Qin, Jianwen; Tang, Yuling; Mu, Xinlin; Gu, Yangchun; Zhang, Shucai; Chen, Xueqin; Pang, Li; Meng, Qingwei; Guo, Ye; Zhang, Yuhui; Li, Wei; Xing, Puyuan; Cheng, Yuan; Xin, Tao; Li, Qingxia; Li, Yu; Chen, Jun; Gao, Feng; Jin, Bo; Rossi, Antonio; Adachi, Hiroyuki; Guerrera, Francesco; Husain, Hatim; Xu, Yan; Wang, Mengzhao |
| Feb-2020 | A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group | Hong, Huangming; Li, Yexiong; Lim, Soon Thye; Liang, Chaoyong; Huang, He; Yi, Pingyong; Wu, Tao; Du, Xin; Zhang, Mingzhi; Wang, Jinghua; Zhu, Jun; Liu, Ting; Meng, Fanyi; Wu, Gang; Guo, Ye; Zhu, Yuan; Zhao, Weili; Jin, Jie; Li, Juan; Deng, Yanming; Gu, Kangsheng; Wu, Xiangyuan; Ke, Xiaoyan; Xie, Derong; Lin, Daren; Peng, Zhigang; Wu, Junxin; Liu, Qing; Kim, Won Seog; Lin, Tongyu |
| 2014 | a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG) | Hong, Huangming; Du, Xin; Zhang, Mingzhi; Wang, Jinghua; Zhu, Jun; Huang, He; Liu, Ting; Meng, Fanyi; Wu, Gang; Guo, Ye; Zhao, Weili; Jin, Jie; Li, Juan; Deng, Yanming; Gu, Kangsheng; Wu, Xiangyuan; Ke, Xiaoyan; Xie, Derong; Lin, Daren; Lin, Tongyu |
| 2017 | Research on calibrating rock mechanical parameters with a statistical method | Liu, Zhen; Guo, Ye; Du, Shuheng; Wu, Gengyu; Pan, Mao |
| 20-May-2020 | Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study. | Li, Jin; Li, Huiping; Qin, Shukui; Guo, Ye; Liang, Xu; Xue, Junli; Peng, Wei; Ge, Xiaoxiao; Xie, Changxing; Yang, Xiugao; Li, Tao; Xu, Jinglin; Feng, Li; Wu, Zhufeng; Xiao, Guanxi; Zhang, Peng; Zhang, Tianyi; Wang, Chenchen; Zhang, Baoxia; Hu, Zijian |
| 1-Jun-2022 | Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC). | Shen, Lin; Guo, Ye; Zhang, Yanqiao; Li, Wei; Gong, Jifang; Li, Qun; Ma, Zhigang; Wang, Nanya; Su, Rila; Cai, Zhongheng; Guo, Rong; Li, Peiqi; Tse, Archie N. |
